Pegstim Indications/Uses

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Pegfilgrastim (Pegstim) is used to decrease the risk of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic cytotoxic chemotherapy that is associated with a clinically important risk of severe neutropenia with fever. Treatment with Pegfilgrastim (Pegstim) leads to significant reductions in the incidence, severity and duration of neutropenia and febrile neutropenia frequently observed in patients undergoing cytotoxic chemotherapy. Patients treated with Pegfilgrastim (Pegstim) and cytotoxic chemotherapy requires fewer and shorter hospitalization and decreased antibiotic usage compared to patients treated with cytotoxic chemotherapy alone; thus leading to a greater likelihood of patient compliance and decreased burden for both patients and healthcare professionals. In the absence of growth factor support, febrile neutropenia or severe neutropenia has been reported in patients receiving similar chemotherapy regimens.